Why the study?
Argatroban and bivalirudin are both used to treat heparin-induced thrombocytopenia, but it was unclear whether either agent offered an advantage in efficacy and maintaining targeted therapeutic anticoagulation.
Does argatroban improve time to therapeutic anticoagulation compared to bivalirudin in patients with suspected or confirmed heparin-induced thrombocytopenia?
Population
91 patients with suspected or confirmed heparin-induced thrombocytopenia
Comparison
Argatroban vs bivalirudin
Design
Single-center retrospective observational cohort study
Authors
Loading...
Argatroban may offer faster therapeutic anticoagulation in suspected HIT; leaves open effects on clinical outcomes.
Does argatroban improve time to therapeutic anticoagulation compared to bivalirudin in patients with suspected or confirmed heparin-induced thrombocytopenia?
Argatroban achieves initial therapeutic anticoagulation goals significantly faster than bivalirudin in patients with suspected or confirmed HIT.
Duewell et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: